{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:09:38Z","timestamp":1761883778987,"version":"build-2065373602"},"reference-count":76,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.reumae.2020.12.002","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T08:30:21Z","timestamp":1627029021000},"page":"611-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis"],"prefix":"10.1016","volume":"17","author":[{"given":"Julio","family":"Casasola-Vargas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Flores-Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis H.","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sicsik-Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Reyes-Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Villanueva Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Amaya Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara G.","family":"Reyes Orozco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz E.","family":"Zazueta Montiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Hern\u00e1ndez-Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lica","family":"Mendoza-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana G.","family":"Bernard-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"L\u00f3pez Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa E.","family":"Barbosa Cobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Burgos-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"Pacheco-Tena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2020.12.002_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/BOR.0000000000000155","article-title":"Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis","volume":"27","author":"Siegel","year":"2015","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0010","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"10.1016\/j.reumae.2020.12.002_bib0015","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun."},{"key":"10.1016\/j.reumae.2020.12.002_bib0020","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/rheumatology\/keq369","article-title":"Incidence and prevalence of psoriatic arthritis in Buenos Aires, Argentina: a 6-year health management organization-based study","volume":"50","author":"Soriano","year":"2011","journal-title":"Rheumatol Oxf Engl."},{"key":"10.1016\/j.reumae.2020.12.002_bib0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jdv.12222","article-title":"New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease","volume":"28","author":"Boehncke","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0050","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013Update 2015\u2013Short version\u2013EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","article-title":"Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations","volume":"12","author":"Gossec","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0060","article-title":"Methotrexate for psoriatic arthritis","volume":"2019","author":"Wilsdon","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.reumae.2020.12.002_bib0065","first-page":"51","article-title":"Efficacy and safety of leflunomide in psoriatic arthritis","volume":"24","author":"Asaduzzaman","year":"2016","journal-title":"J Pak Assoc Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0070","first-page":"728","article-title":"The effectiveness of leflunomide in psoriatic arthritis","volume":"32","author":"Asiri","year":"2014","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reumae.2020.12.002_bib0080","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0090","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0095","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial","volume":"22","author":"Gupta","year":"1995","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0100","first-page":"1957","article-title":"The use of sulfasalazine in psoriatic arthritis: a clinic experience","volume":"25","author":"Rahman","year":"1998","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0105","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol."},{"issue":"1 Suppl 95","key":"10.1016\/j.reumae.2020.12.002_bib0110","first-page":"S12","article-title":"Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure","volume":"34","author":"Lythgoe","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0115","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0120","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.reumae.2020.12.002_bib0125","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.reumae.2020.12.002_bib0135","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"10.1016\/j.reumae.2020.12.002_bib0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2020.12.002_bib0145","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2020.12.002_bib0150","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0155","first-page":"869","article-title":"Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0160","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0170","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","article-title":"Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study","volume":"20","author":"Coates","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reumae.2020.12.002_bib0180","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0185","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0190","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/rheumatology\/key161","article-title":"Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-na\u00efve patients with active psoriatic arthritis (SPIRIT-P1)","volume":"57","author":"Gottlieb","year":"2018","journal-title":"Rheumatol Oxf Engl."},{"key":"10.1016\/j.reumae.2020.12.002_bib0195","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.reumae.2020.12.002_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000692","volume":"4","author":"Nash","year":"2018","journal-title":"RMD Open."},{"key":"10.1016\/j.reumae.2020.12.002_bib0205","series-title":"Oral presentations","first-page":"261","author":"Mease","year":"2019"},{"key":"10.1016\/j.reumae.2020.12.002_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reumae.2020.12.002_bib0215","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0220","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/imt-2018-0014","article-title":"Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders","volume":"10","author":"Zizzo","year":"2018","journal-title":"Immunotherapy."},{"key":"10.1016\/j.reumae.2020.12.002_bib0225","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reumae.2020.12.002_bib0230","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reumae.2020.12.002_bib0235","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized. Controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0240","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0245","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/BOR.0b013e32835fd8d5","article-title":"Psoriatic arthritis and spondyloarthritis assessment and management update","volume":"25","author":"Mease","year":"2013","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0255","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/17512433.2018.1548277","article-title":"Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis","volume":"11","author":"Stiff","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0260","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0265","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0270","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0275","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2020.12.002_bib0280","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/annrheumdis-2013-203697","article-title":"Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol","volume":"73","author":"van der Heijde","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00296-017-3919-7","article-title":"Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis","volume":"38","author":"Kawalec","year":"2018","journal-title":"Rheumatol Int."},{"key":"10.1016\/j.reumae.2020.12.002_bib0295","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2020.12.002_bib0300","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0310","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","article-title":"Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0315","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0320","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-017-3917-x","article-title":"A resistance exercise program improves functional capacity of patients with psoriatic arthritis: a randomized controlled trial","volume":"37","author":"Roger-Silva","year":"2018","journal-title":"Clin Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0325","first-page":"1106","article-title":"Isolated peripheral enthesitis and\/or dactylitis: a subset of psoriatic arthritis","volume":"24","author":"Salvarani","year":"1997","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0330","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.reumae.2020.12.002_bib0335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reumae.2020.12.002_bib0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/acr.23111","article-title":"Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized. Double-blind placebo-controlled study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.reumae.2020.12.002_bib0345","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3899\/jrheum.160275","article-title":"Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study","volume":"43","author":"Kavanaugh","year":"2016","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0355","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/annrheumdis-2017-eular.1165","article-title":"Intravenous golimumab in adult patients with active psoriatic arthritis: efficacy and safety through week 24","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2020.12.002_bib0360","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0365","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0370","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjd.12632","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0375","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J Dermatol."},{"key":"10.1016\/j.reumae.2020.12.002_bib0380","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","article-title":"Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?","volume":"59","author":"Feld","year":"2020","journal-title":"Rheumatol (Oxford)."}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574321001398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:59:51Z","timestamp":1761879591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574321001398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2173574321001398"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2020.12.002","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2020.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2020.12.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}